-
1
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
2
-
-
33746326784
-
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
-
DOI 10.1016/j.ejca.2006.01.065, PII S0959804906005466
-
Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671-1683. (Pubitemid 44118778)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.11
, pp. 1671-1683
-
-
Sirohi, B.1
Powles, R.2
-
3
-
-
84868341496
-
-
Clinical Trials.gov: a service of the US National Institutes of Health. Available at: Accessed December 14, 2010
-
Clinical Trials.gov: a service of the US National Institutes of Health. Search of studies with lenalidomide and newly diagnosed multiple myeloma. Available at: http://clinicaltrials.gov/ct2/results?term= lenalidomide+and+newly+diagnosed+multiple+myeloma. Accessed December 14, 2010.
-
Search of Studies with Lenalidomide and Newly Diagnosed Multiple Myeloma
-
-
-
4
-
-
77955451933
-
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches
-
Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51:1424-1443.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 1424-1443
-
-
Engelhardt, M.1
Kleber, M.2
Udi, J.3
-
5
-
-
75649085683
-
Current multiple myeloma treatment strategies with novel agents: A European perspective
-
Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15:6-25.
-
(2010)
Oncologist
, vol.15
, pp. 6-25
-
-
Ludwig, H.1
Beksac, M.2
Bladé, J.3
-
6
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
Multiple Myeloma (009) Study Investigators
-
Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
-
(2007)
N Engl J Med
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
-
7
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Multiple Myeloma (010) Study Investigators
-
Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
-
(2007)
N Engl J Med
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
-
8
-
-
67649985917
-
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
-
Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164-170.
-
(2009)
Br J Haematol
, vol.146
, pp. 164-170
-
-
Chen, C.1
Reece, D.E.2
Siegel, D.3
-
9
-
-
65349097489
-
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
-
Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426-432.
-
(2009)
Eur J Haematol
, vol.82
, pp. 426-432
-
-
Stadtmauer, E.A.1
Weber, D.M.2
Niesvizky, R.3
-
10
-
-
77949463293
-
Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone
-
ASH Annual Meeting Abstracts
-
Ishak J, Dimopoulus MA, Weber D, Knight RD, Shearer A, Caro J. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting Abstracts). 2008;112:3708.
-
(2008)
Blood
, vol.112
, pp. 3708
-
-
Ishak, J.1
Dimopoulus, M.A.2
Weber, D.3
Knight, R.D.4
Shearer, A.5
Caro, J.6
-
11
-
-
73249146496
-
Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An openlabel randomised controlled trial
-
Eastern Cooperative Oncology Group
-
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME. Eastern Cooperative Oncology Group. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11:29-37.
-
(2010)
Lancet Oncol
, vol.11
, pp. 29-37
-
-
Rajkumar, S.V.1
Jacobus, S.2
Callander, N.S.3
Fonseca, R.4
Vesole, D.H.5
Williams, M.E.6
-
12
-
-
33845350847
-
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy
-
DOI 10.1093/annonc/mdl313, Special Issue: Gender and the Politics of Scale
-
Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17:1766-1771. (Pubitemid 44884050)
-
(2006)
Annals of Oncology
, vol.17
, Issue.12
, pp. 1766-1771
-
-
Baz, R.1
Walker, E.2
Karam, M.A.3
Choueiri, T.K.4
Jawde, R.A.5
Bruening, K.6
Reed, J.7
Faiman, B.8
Ellis, Y.9
Brand, C.10
Srkalovic, G.11
Andresen, S.12
Knight, R.13
Zeldis, J.14
Hussein, M.A.15
-
13
-
-
66149109580
-
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
-
Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137-4143.
-
(2009)
Blood
, vol.113
, pp. 4137-4143
-
-
Knop, S.1
Gerecke, C.2
Liebisch, P.3
-
14
-
-
35348923502
-
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian Multiple Myeloma Network
-
DOI 10.1200/JCO.2007.12.3463
-
Palumbo A, Falco P, Corradini P, et al. GIMEMA - Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465. (Pubitemid 350063804)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.28
, pp. 4459-4465
-
-
Palumbo, A.1
Falco, P.2
Corradini, P.3
Falcone, A.4
Di, R.F.5
Giuliani, N.6
Crippa, C.7
Ciccone, G.8
Omede, P.9
Ambrosini, M.T.10
Gay, F.11
Bringhen, S.12
Musto, P.13
Foa, R.14
Knight, R.15
Zeldis, J.B.16
Boccadoro, M.17
Petrucci, M.T.18
-
15
-
-
38949216066
-
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
-
DOI 10.1182/blood-2007-05-090258
-
Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101-1109. (Pubitemid 351213388)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1101-1109
-
-
Niesvizky, R.1
Jayabalan, D.S.2
Christos, P.J.3
Furst, J.R.4
Naib, T.5
Ely, S.6
Jalbrzikowski, J.7
Pearse, R.N.8
Zafar, F.9
Pekle, K.10
LaRow, A.11
Lent, R.12
Mark, T.13
Cho, H.J.14
Shore, T.15
Tepler, J.16
Harpel, J.17
Schuster, M.W.18
Mathew, S.19
Leonard, J.P.20
Mazumdar, M.21
Chen-Kiang, S.22
Coleman, M.23
more..
-
16
-
-
42649116903
-
Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): Analysis from MM-009 and MM-010 randomized phase III clinical trials
-
ASH Annual Meeting Abstracts
-
Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting Abstracts). 2006;108:3554.
-
(2006)
Blood
, vol.108
, pp. 3554
-
-
Chanan-Khan, A.A.1
Yu, Z.2
Weber, D.3
-
17
-
-
34547625141
-
Lenalidomide (Revlimid) costicosteroid in elderly patients with relapsed/refractory multiple myeloma
-
ASH Annual Meeting Abstracts
-
Reece D, Masih-Khan, Chen C, et al. Lenalidomide (Revlimid) costicosteroid in elderly patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108:3550.
-
(2006)
Blood
, vol.108
, pp. 3550
-
-
Reece, D.1
Masih-Khan2
Chen, C.3
-
18
-
-
39149109289
-
Prevention of thalidomide and lenalidomide associated trombosis in myeloma
-
International Myeloma Working Group
-
Palumbo A, Rajkumar SV, Dimopoulus MA, et al. International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 2008;22:414-423.
-
(2008)
Leukemia
, vol.22
, pp. 414-423
-
-
Palumbo, A.1
Rajkumar, S.V.2
Dimopoulus, M.A.3
-
19
-
-
0037208595
-
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
-
Weber D, Rankin K, Gavion M, Dalasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
-
(2003)
J Clin Oncol
, vol.21
, pp. 16-19
-
-
Weber, D.1
Rankin, K.2
Gavion, M.3
Dalasalle, K.4
Alexanian, R.5
-
20
-
-
0036846653
-
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma
-
Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377-3382. (Pubitemid 35340711)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.11
, pp. 3377-3382
-
-
Neben, K.1
Moehler, T.2
Benner, A.3
Kraemer, A.4
Egerer, G.5
Ho, A.D.6
Goldschmidt, H.7
-
21
-
-
0035469858
-
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
-
Zangari M, Anaissie E, Barlogi B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
-
(2001)
Blood
, vol.98
, pp. 1614-1615
-
-
Zangari, M.1
Anaissie, E.2
Barlogi, B.3
-
22
-
-
33745590139
-
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis [5]
-
DOI 10.1182/blood-2006-01-0154
-
Zonder JA, Barlogie B, Durie DG, Mc Coy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (ASH Annual Meeting Abstracts). 2006;108:403. (Pubitemid 43990659)
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 403
-
-
Zonder, J.A.1
Barlogie, B.2
Durie, B.G.M.3
McCoy, J.4
Crowley, J.5
Hussein, M.A.6
-
23
-
-
79959765455
-
Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens
-
ASH Annual Meeting Abstracts
-
Brandenburg NA, Goss TF, Knight T, Xu X, Knight RD. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens. Blood (ASH Annual Meeting Abstracts). 2008;112:2369.
-
(2008)
Blood
, vol.112
, pp. 2369
-
-
Brandenburg, N.A.1
Goss, T.F.2
Knight, T.3
Xu, X.4
Knight, R.D.5
-
24
-
-
73949154067
-
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone
-
Zangari M, Tricot G, Poavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J Clin Oncol. 2009;28:132-135.
-
(2009)
J Clin Oncol
, vol.28
, pp. 132-135
-
-
Zangari, M.1
Tricot, G.2
Poavaram, L.3
-
25
-
-
79959753459
-
Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: Aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors
-
ASH Annual Meeting Abstracts
-
Wright JA, Weber D, Thomas SK, et al. Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors. Blood (ASH Annual Meeting Abstracts). 2007;110:1882.
-
(2007)
Blood
, vol.110
, pp. 1882
-
-
Wright, J.A.1
Weber, D.2
Thomas, S.K.3
-
26
-
-
57049113927
-
Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
-
Klein U, Kosely F, Hillegab J, et al. Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009:88:67-71.
-
(2009)
Ann Hematol
, vol.88
, pp. 67-71
-
-
Klein, U.1
Kosely, F.2
Hillegab, J.3
|